VoxelotorMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/oxbryta-voxelotor
2024
false
false
false
France
French
risk management
voxelotor
voxelotor
administration, oral
hematologic agents
drug information
anemia, hemolytic
anemia, sickle cell
Safety-Based drug withdrawals

---
https://ansm.sante.fr/informations-de-securite/oxbryta-voxelotor-suspension-de-lautorisation-de-mise-sur-le-marche-de-lunion-europeenne
https://ansm.sante.fr/actualites/oxbryta-voxelotor-conduite-a-tenir-suite-a-la-suspension-de-lautorisation-de-mise-sur-le-marche
2024
false
false
false
France
French
Safety-Based drug withdrawals
voxelotor
pharmacovigilance note
voxelotor
guidelines for drug use
drugs, investigational
france
europe
hematologic agents
Vaso-Occlusive Crisis

---
https://www.has-sante.fr/jcms/p_3448025/fr/oxbryta-voxelotor-anemie-hemolytique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
voxelotor
hematologic agents
anemia, sickle cell
adult
adolescent
summary of product characteristics
drug therapy, combination
evaluation of the transparency committee
voxelotor
anemia, hemolytic

---
Suspended - This medicine is currently suspended from use in the European Union
https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
voxelotor
voxelotor
voxelotor
orphan drug production
anemia, sickle cell
Oxbryta
drug approval
europe
adolescent
adult
administration, oral
aged
hematologic agents
hematologic agents
product surveillance, postmarketing
pregnancy
breast feeding
drug therapy, combination
drug interactions
hemoglobin, sickle
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3361556/fr/oxbryta-voxelotor-anemie-hemolytique-severe
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
voxelotor
administration, oral
hematologic agents
adult
adolescent
drug therapy, combination
hydroxyurea
evaluation of the transparency committee
Oxbryta
voxelotor
anemia, sickle cell

---
https://www.has-sante.fr/jcms/p_3348600/fr/oxbryta-voxelotor-carcinome-urothelial-anemie-hemolytique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
voxelotor
drug therapy, combination
anemia, sickle cell
administration, oral
voxelotor
hydroxyurea
adult
adolescent
evaluation of the transparency committee
voxelotor

---
https://ansm.sante.fr/tableau-atu-rtu/voxelotor-500-mg-comprimes-pellicules
2021
false
false
false
France
French
voxelotor
anemia, sickle cell
Product containing only voxelotor in oral dose form (medicinal product form)
guidelines for drug use
voxelotor
benzaldehydes
pyrazines
pyrazoles

---